A number of other institutional investors and hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after acquiring an additional 3,912,430 shares during the period. Legal & General Group Plc raised its holdings in Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after acquiring an additional 421,779 shares during the period. FMR LLC grew its position in shares of Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Johnson & Johnson by 1.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, California Public Employees Retirement System grew its position in shares of Johnson & Johnson by 2.7% during the 3rd quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock worth $1,919,726,000 after purchasing an additional 310,473 shares in the last quarter. 67.94% of the stock is owned by institutional investors.
Insider Activity
In other news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 181,955 shares of company stock valued at $32,081,502. Insiders own 0.35% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on JNJ. Atlantic Securities increased their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Piper Sandler decreased their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. SVB Leerink decreased their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $175.71.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $162.04 on Wednesday. The company has a market cap of $423.65 billion, a price-to-earnings ratio of 24.04, a PEG ratio of 2.79 and a beta of 0.54. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The firm has a 50 day simple moving average of $172.25 and a 200 day simple moving average of $170.03. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.94%. The firm’s revenue was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.13 EPS. Research analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is currently 67.06%.
About Johnson & Johnson
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Featured Articles
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.